Skip to Content

Generic Mavyret Availability

Mavyret is a brand name of glecaprevir/pibrentasvir, approved by the FDA in the following formulation(s):

MAVYRET (glecaprevir; pibrentasvir - tablet;oral)

  • Manufacturer: ABBVIE INC
    Approval date: August 3, 2017
    Strength(s): 100MG;40MG [RLD]

Has a generic version of Mavyret been approved?

No. There is currently no therapeutically equivalent version of Mavyret available in the United States.

Note: Fraudulent online pharmacies may attempt to sell an illegal generic version of Mavyret. These medications may be counterfeit and potentially unsafe. If you purchase medications online, be sure you are buying from a reputable and valid online pharmacy. Ask your health care provider for advice if you are unsure about the online purchase of any medication.

See also: Generic Drug FAQs.

Related Patents

Patents are granted by the U.S. Patent and Trademark Office at any time during a drug's development and may include a wide range of claims.

  • Macrocyclic proline derived HCV serine protease inhibitors
    Patent 8,648,037
    Issued: February 11, 2014
    Assignee(s): Enanta Pharmaceuticals, Inc.
    The present invention discloses compounds of Formula I or pharmaceutically acceptable salts, esters, or prodrugs thereof: which inhibit serine protease activity, particularly the activity of hepatitis C virus (HCV) NS3-NS4A protease. Consequently, the compounds of the present invention interfere with the life cycle of the hepatitis C virus and are also useful as antiviral agents. The present invention further relates to pharmaceutical compositions comprising the aforementioned compounds for administration to a subject suffering from HCV infection. The invention also relates to methods of treating an HCV infection in a subject by administering a pharmaceutical composition comprising the compounds of the present invention.
    Patent expiration dates:
    • January 19, 2032
      ✓ 
      Patent use: TREATMENT OF CHRONIC HEPATITIS C VIRUS (HCV) GENOTYPE 1, 2, 3, 4, 5, OR 6
      ✓ 
      Drug substance
      ✓ 
      Drug product
  • Anti-viral compounds
    Patent 8,937,150
    Issued: January 20, 2015
    Assignee(s): AbbVie Inc.
    Compounds effective in inhibiting replication of Hepatitis C virus (“HCV”) are described. This invention also relates to processes of making such compounds, compositions comprising such compounds, and methods of using such compounds to treat HCV infection.
    Patent expiration dates:
    • May 18, 2032
      ✓ 
      Drug substance
      ✓ 
      Drug product
  • Crystal forms
    Patent 9,321,807
    Issued: April 26, 2016
    Assignee(s): AbbVie Inc.
    The present invention features crystalline forms of Compound I. In one embodiment, a crystalline form of Compound I has characteristic peaks in the PXRD pattern as shown in any one of FIGS. 1-4.
    Patent expiration dates:
    • June 5, 2035
      ✓ 
      Drug substance
  • Anti-viral compounds
    Patent 9,586,978
    Issued: March 7, 2017
    Assignee(s): AbbVie Inc.
    Compounds effective in inhibiting replication of Hepatitis C virus (“HCV”) are described. This invention also relates to processes of making such compounds, compositions comprising such compounds, and methods of using such compounds to treat HCV infection.
    Patent expiration dates:
    • June 10, 2030
      ✓ 
      Patent use: TREATMENT OF CHRONIC HEPATITIS C VIRUS (HCV) GENOTYPE 1, 2, 3, 4, 5, OR 6

Related Exclusivities

Exclusivity is exclusive marketing rights granted by the FDA upon approval of a drug and can run concurrently with a patent or not. Exclusivity is a statutory provision and is granted to an NDA applicant if statutory requirements are met.

  • Exclusivity expiration dates:
    • August 3, 2022 - NEW CHEMICAL ENTITY
Glossary
TermDefinition
Drug PatentA drug patent is assigned by the U.S. Patent and Trademark Office and assigns exclusive legal right to the patent holder to protect the proprietary chemical formulation. The patent assigns exclusive legal right to the inventor or patent holder, and may include entities such as the drug brand name, trademark, product dosage form, ingredient formulation, or manufacturing process A patent usually expires 20 years from the date of filing, but can be variable based on many factors, including development of new formulations of the original chemical, and patent infringement litigation.
Drug ExclusivityExclusivity is the sole marketing rights granted by the FDA to a manufacturer upon the approval of a drug and may run simultaneously with a patent. Exclusivity periods can run from 180 days to seven years depending upon the circumstance of the exclusivity grant.
RLDA Reference Listed Drug (RLD) is an approved drug product to which new generic versions are compared to show that they are bioequivalent. A drug company seeking approval to market a generic equivalent must refer to the Reference Listed Drug in its Abbreviated New Drug Application (ANDA). By designating a single reference listed drug as the standard to which all generic versions must be shown to be bioequivalent, FDA hopes to avoid possible significant variations among generic drugs and their brand name counterpart.
Hide